Study Demonstrates 12-Month Relief of Post-Amputation Pain Following Treatment With SPRINT PNS System
CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced publication of 12-month follow up results of its SPRINT® Peripheral Nerve Stimulation (PNS) System used for the treatment of post-amputation pain. The SPRINT System is the only FDA-cleared short-term PNS treatment that has demonstrated an ability to provide long-term pain relief, with corresponding improvements in function and depression.
The double-blinded, randomized controlled study was awarded “Best of Meeting” at the 18th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine in New Orleans and has now been published in the society’s official journal, Regional Anesthesia and Pain Medicine.
Study participants had experienced post-amputation pain for up to 30 years. All participants underwent ultrasound-guided placement of SPR’s MicroLeads™ which are constructed using a tiny 100-micron wire, about the size of a human hair. Participants were then randomized to receive treatment using SPRINT PNS for 8 weeks, or placebo for four weeks and SPRINT PNS for 4 weeks.
While 67% of the participants in the treatment group reported = 50% reductions in pain 12 months after the start of the 8-week stimulation treatment, none of the participants in placebo group demonstrated these results at the end of the placebo period. Treatment group participants also reported significantly less interference of pain in walking, sleeping, enjoyment of life, and general activity.
Dr. Christopher Gilmore of the Center for Clinical Research in Winston-Salem, NC and principal author, stated: “The results are quite provocative and lead one to question whether a permanently implanted neurostimulation device is necessary for many patients who respond to a temporarily implanted lead. It i also encouraging to see that results are similar to those we’ve seen in patients with low back pain and shoulder pain.”
“This latest study builds on the growing body of evidence demonstrating that our SPRINT PNS System is able to deliver sustained and significant pain relief after the completion of its 60-day treatment,” said Maria Bennett, CEO of SPR Therapeutics, Inc. “We are also encouraged by SPRINT’s early commercial success and look forward to working with our many physician partners to expand the availability of this treatment to patients who could benefit from a non-opioid and non-surgical solution for their pain.”
About SPRINT® PNS System
About SPR Therapeutics, Inc.
About this study
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bbb58e8a-3aff-4593-b57c-d9913f7e740e
Protecting Critical Infrastructure with Epic Security
TESLA GIVEAWAY DRAWING - Mist be present to Win
The Why and How of Edge Intelligence Tools